---
title: "European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278581504.md"
description: "European equities traded in the US as American depositary receipts rose 1.12% to 1,777.07 on the S&P Europe Select ADR Index. Notable gainers included Evaxion (8.4%) and Cellectis (5.6%), while decliners included BioNTech (-21%) and Natuzzi (-18%). From the UK and Ireland, Akari Therapeutics (6.6%) and NuCana (5.1%) led the gains, whereas Trinity Biotech (-8.1%) and Endava (-4%) were the biggest decliners."
datetime: "2026-03-10T15:10:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278581504.md)
  - [en](https://longbridge.com/en/news/278581504.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278581504.md)
---

# European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

11:10 AM EDT, 03/10/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12% to 1,777.07 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion ( EVAX ) and biopharmaceutical company Cellectis ( CLLS ) , which climbed 8.4% and 5.6% respectively. They were followed by biopharmaceutical company DBV Technologies ( DBVT ) and lender Banco Santander (SAN), which advanced 3.7% and 3.1% respectively.

The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and furniture maker Natuzzi (NTZ), which tumbled 21% and 18% respectively. They were followed by biopharmaceutical company Grifols ( GRFS ) and pharmaceutical company Novo Nordisk ( NVO ) , which lost 4.1% and 3.2% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics ( AKTX ) and NuCana ( NCNA ) , which rose 6.6% and 5.1% respectively. They were followed by biopharmaceutical company Amarin ( AMRN ) and pharmaceutical company Silence Therapeutics ( SLN ) , which were up 3.6% and 2.8% respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech ( TRIB ) and software company Endava ( DAVA ) , which dropped 8.1% and 4% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals ( BDRX ) and communications company WPP ( WPP ) , which lost 2.6% and 1.6% respectively.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)
- [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md)
- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)
- [TRIB.US](https://longbridge.com/en/quote/TRIB.US.md)
- [DAVA.US](https://longbridge.com/en/quote/DAVA.US.md)
- [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md)
- [NCNA.US](https://longbridge.com/en/quote/NCNA.US.md)
- [SPEU.US](https://longbridge.com/en/quote/SPEU.US.md)
- [FDD.US](https://longbridge.com/en/quote/FDD.US.md)

## Related News & Research

- [Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | AKTX Stock News](https://longbridge.com/en/news/286776452.md)
- [Akari reports preclinical AKTX-101 synergy with KRAS inhibitor in pancreatic cancer models](https://longbridge.com/en/news/287273431.md)
- [Endava plc Stock 12‑Month Price Target Cut to $8.28, Implies 107% Upside](https://longbridge.com/en/news/287263782.md)
- [UK's Endava Q3 revenue falls 8.4% on weak demand, posts goodwill impairment](https://longbridge.com/en/news/287210665.md)
- [BioNTech's founding couple Sahin, Tuereci to leave to set up new venture](https://longbridge.com/en/news/278538947.md)